Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04621890 · ClinicalTrials.gov registry record · NA

HCT Cash-Only INcentive to Promote Mealtime Insulin DOSE Engagement

A NA study of Type 1 Diabetes, sponsored by Children's Mercy Hospital Kansas City.

Completed
Registry status
NA
Development phase
39
Enrollment target
1
Study location

NCT04621890: Completed NA study of Type 1 Diabetes, sponsored by Children's Mercy Hospital Kansas City.

NCT04621890 is a NA study of Type 1 Diabetes that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 39 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04621890, a NA study of Type 1 Diabetes, has completed, sponsored by Children's Mercy Hospital Kansas City.

COMPLETED
Registry status
NA
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

Type 1 Diabetes (T1D) is a serious disease that happens because the body cannot control blood glucose (sugar) levels. People with T1D need insulin shots because their body does not make insulin. Insulin lowers blood sugar levels. When blood sugar levels are too high or too low it causes medical problems. Youth with T1D can really impact their own health if they follow their T1D treatment plan. However, even with the help of doctors, nurses, and family, most adolescents find it hard to follow their diabetes plan close enough to meet their A1C goal. It is very common for adolescents to forget to give an insulin bolus for meals. When insulin doses are missed, there is a greater chance for poor blood sugar control. When adolescents follow their diabetes plan closely, they have better blood sugar control and overall health. Two behavioral economic interventions will be evaluated. COIN2DOSE (Cash-Only INcentive to promote mealtime insulin DOSE Engagement) and LOAN2DOSE (Behavioral Economic concept that uses an economic loss aversion approach to promote insulin dose engagement in adolescents with Type 1 Diabetes). These programs were designed to improve blood sugar control by decreasing the number of missed mealtime boluses. For COIN2DOSE, we will offer the opportunity for youth to earn a bonus reimbursement during which they achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will pay youth up for sharing their insulin use data at least two times per week with the study team during the three-month treatment phase. For LOAN2DOSE, the participants will start with a monetary "balance" and will keep it if they bolus as instructed - at least 5 days of 3 mealtime insulin boluses. If they do not do this, their balance will decrease throughout the study.

Primary Outcome

A1C is a validated indicator of glycemic control.

Conditions Studied

Interventions

  • BEHAVIORAL LOAN2DOSE and COIN2DOSE

Study Locations (1)

Kansas

  • Children's Mercy Kansas City - Kansas City

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2022-02-14
Est. Completion 2025-06-30
Phase NA

What the finished NCT04621890 record still lists

NCT04621890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which LOAN2DOSE and COIN2DOSE is the first listed.

NCT04621890 reports a single indexed study location in Kansas.

Frequently Asked Questions

What is clinical trial NCT04621890 about?

NCT04621890 is a clinical study titled "HCT Cash-Only INcentive to Promote Mealtime Insulin DOSE Engagement". Type 1 Diabetes (T1D) is a serious disease that happens because the body cannot control blood glucose (sugar) levels. People with T1D need insulin shots because their body does not make insulin. Insulin lowers blood sugar levels. When blood sugar levels are too high or too low it causes medical prob...

What is the current status of trial NCT04621890?

This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2022-02-14. Estimated completion is 2025-06-30.

What conditions does trial NCT04621890 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT04621890?

The interventions under investigation include: LOAN2DOSE and COIN2DOSE (BEHAVIORAL).

Who is sponsoring clinical trial NCT04621890?

This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04621890 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04621890's enrollment target sits among peer trials

39 108th of 198 higher than 89 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03465592 · 39 participants · Phase 1

    Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

  • NCT03961776 · 39 participants

    Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems

  • NCT04050280 · 39 participants · Phase 2

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

  • NCT04190862 · 39 participants · Phase 1

    E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04621890, the US trial registry maintained by the National Library of Medicine. NCT04621890 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.